As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
- Novartis to Cut 2,000 Jobs in Manufacturing, Development Division
October 28, 2011
- Hisamitsu Forms Chinese Subsidiary to Enter OTC Business
October 28, 2011
- JDF, Eli Lilly Japan Create Subsidy Program for Basic Incretin Research
October 28, 2011
- Nitto Denko, Maruho Apply for Additional Indication for Penles Tape for Pain Relief with Removal of Warts
October 28, 2011
- Bayer to Continue to Discuss Filing for Approval for Regorafenib in Europe, US after Improvement of OS in PIII Trial
October 28, 2011
- Baxter's Worldwide Sales Up 10% to US$10.3 Bil. for 1st Nine Months of 2011
October 28, 2011
- Terumo: Record Sales, Operating Profits in 1st Half of FY2011
October 28, 2011
- Nexium Tops HP Market in September Led by 2 Active Marketers: RepTrack Survey
October 27, 2011
- DSP to Distribute iPad2 to All MRs from Jan. Next Year
October 27, 2011
- Takara Bio Upwardly Revises Profit Forecasts for 1st Half of FY2012
October 27, 2011
- Sales of Top 30 Drug Wholesalers Up 1.9% in 2010: Yano Research Institute
October 27, 2011
- Wholesalers Expecting Some Increase in Price Gap in Next Market Price Survey
October 27, 2011
- GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
- Nippon Chemiphar Revises Business Forecasts for 1st Half of FY2012
October 26, 2011
- Perpetuation of Premium for New Drug Development Discussed at IMS Japan Symposium
October 26, 2011
- Wakamoto Revises the Full-Year Consolidated Forecasts Expecting Deficit Reduction
October 25, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…